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Obesity, type 2 diabetes, and cardiovascular disease correlate with
infiltration to adipose tissue of different immune cells, with uncertain
influences on metabolism. Rats were fed a diet high in carbohydrates
and saturated fats to develop diet-induced obesity over 16 weeks.
This nutritional overload caused overexpression and secretion of
phospholipase A2 group IIA (pla2g2a) from immune cells in adipose
tissue rather than adipocytes, whereas expression of adipose-spe-
cific phospholipase A2 (pla2g16) was unchanged. These immune
cells produce prostaglandin E2 (PGE2), which influences adipo-
cyte signaling. We found that a selective inhibitor of human
pla2g2a (5-(4-benzyloxyphenyl)-(4S)-(phenyl-heptanoylamino)-
pentanoic acid [KH064]) attenuated secretion of PGE2 from hu-
man immune cells stimulated with the fatty acid, palmitic acid, or
with lipopolysaccharide. Oral administration of KH064 (5 mg/kg/
day) to rats fed the high-carbohydrate, high-fat diet prevented
the overexpression of pla2g2a and the increased macrophage
infiltration and elevated PGE2 concentrations in adipose tissue.
The treatment also attenuated visceral adiposity and reversed
most characteristics of metabolic syndrome, producing marked
improvements in insulin sensitivity, glucose intolerance, and car-
diovascular abnormalities. We suggest that pla2g2a may have
a causal relationship with chronic adiposity and metabolic syn-
drome and that its inhibition in vivo may be a valuable new
approach to treat obesity, type 2 diabetes, and metabolic dysfunc-
tion in humans. Diabetes 61:2320–2329, 2012
Obesity is a complex chronic condition in whichexcess adiposity predisposes the interacting me-tabolic and immune systems to continuous stress(1–4). Among the dynamic components of adi-
pose tissue are adipocytes and many different immune cells,
including macrophages, monocytes, T cells, and mast cells,
that contribute to adipocyte function (5–7). Stress caused
by nutritional overload is associated with initial infiltration
of neutrophils, T cells, and mast cells into adipose, followed
during chronic overload by macrophages, leading to adipocyte
dysfunction and metabolic and cardiovascular abnormalities
that characterize metabolic syndrome (4). Genetic ablation
or chemical intervention that reduces immune cell infil-
tration or action in adipose tissue can prevent or treat diet-
induced obesity in rodents (5–8). Recent studies implicate
novel roles for immune cells, such as macrophages, in
regulating lipolysis during diet-induced obesity (8). Weight
loss induced by calorie restriction is also associated with
transient recruitment of macrophages to white adipose
tissue, indicating a role for macrophages as transporters of
fatty acids during lipolysis (8). Macrophages were predicted
to facilitate trafficking of lipids from white adipose tissue,
probably to the liver for metabolism, based on the tran-
sient recruitment patterns and expression of scavenger
receptors and lipid-handling genes (8,9). However, precise
mechanisms for macrophage regulation of adipose tissue
lipolysis remain unknown. Whether macrophages and
other immune cells exert endocrine or paracrine control of
adipocytes to regulate lipolysis in diet-induced obesity has
not been reported (9).
The turnover rate of adipocytes is similar for lean and
obese individuals (10), but the rate of lipid storage and
removal from adipocytes differs between healthy humans
and people with obesity or hyperlipidemia (11). The tri-
glyceride content is renewed an average of six times dur-
ing the 10-year life span of human adipocytes, whereas
rates of triglyceride storage increase and their removal
decreases in obese versus lean individuals (11). Thus, in-
creased lipid storage in adipocytes, combined with de-
creased removal, contributes to development of obesity
and adipocyte dysfunction in humans (11,12). Pharma-
ceutical interventions are under investigation to decrease
fat stores in adipose tissue and improve adipocyte function
by stimulating lipolysis and oxidation of released fatty
acids (13).
The lipolysis of triglycerides to free fatty acids and glyc-
erol is tightly regulated in adipose tissue by hormones
or enzymes (14). Inflammatory cells, such as mast cells,
neutrophils, and macrophages, express phospholipase A2
(PLA2) enzymes that are involved in various physiologic
processes, including lipid metabolism and cellular signaling
(14,15). Adipose-specific phospholipase A2 group XVI
(pla2g16) and prostaglandin E2 (PGE2) may play important
autocrine and paracrine roles in ob/ob and db/db knockout
mice in regulating lipolysis through a PGE2–prostaglandin
EP3 receptor–cAMP pathway (14,16). PGE2 is strongly
linked to antilipolytic responses in adipocytes by acting
through the Gai-coupled EP3 receptor (14,17,18). However,
secretory PLA2 group IIA (pla2g2a) is mainly recognized for
its role in chronic inflammatory diseases and generation of
PGE2 and other eicosanoids after immune cell activation
(15,19,20).
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ORIGINAL ARTICLE
This study has specifically investigated the role of
pla2g2a, and the therapeutic potential of its inhibition, in
adipose tissue during diet-induced obesity in a rat model
relevant to human disease. The findings support a new
hypothesis that inhibition of pla2g2a may reverse and
protect against adiposity and metabolic dysfunction in diet-
induced obese rats and suggest a mechanism of promoting
lipolysis to enhance fat utilization and energy expenditure.
The pharmacologic responses of a selective pla2g2a in-
hibitor (5-(4-benzyloxyphenyl)-(4S)-(phenyl-heptanoylamino)-
pentanoic acid [KH064]) were not related to direct effects
on adipocytes but rather to decreasing PGE2 release from
immune cells (e.g., macrophages, T cells, monocytes, and
mast cells) also resident in adipose tissue. This in-
hibitor stimulated lipolysis in adipose tissue, suggesting
a novel mechanism for immune cells regulating lipoly-
sis through the PGE2-EP3-cAMP pathway in diet-induced
obesity.
RESEARCH DESIGN AND METHODS
Animals and diets.Male Wistar rats were bred at The University of Queensland
Biological Resources facility. All experimental protocols were approved by the
Animal Experimentation Ethics Committee of TheUniversity of Queensland. The
cornstarch (CS) and high-carbohydrate high-fat (HCHF) diets have been pre-
viously described (21). KH064 (5 mg/kg/day suspended in olive oil) was ad-
ministered daily by oral gavage to HCHF rats, starting at week 8 of the study
protocol. C57BL/6 mice, used for gene expression studies, were fed with a high-fat
diet for 16 weeks.
Adipose tissue analysis. Postmortem retroperitoneal, mesenteric, and epi-
didymal fat depots were collected and weighed immediately. The retroperi-
toneal depot was defined as adipose tissue located behind the kidney, along the
back of the abdomen. All molecular analyses have been done in retroperitoneal
whole adipose tissue as a major component of abdominal fat. Retroperito-
neal rat whole adipose tissue was digested using collagenase B and was
differentially centrifuged to derive floating adipocyte and stromal vascular cell
(SVC) fractions. To assess lipolysis, retroperitoneal whole adipose tissue
explants were incubated in Kreb’s Ringer bicarbonate HEPES for 2 h, with or
without PGE2. Glycerol levels were measured using Free Glycerol Reagent
(Sigma-Aldrich).
Gene expression. RNA was extracted using Qiazol reagent according to the
RNeasy mini kit (Qiagen). RT-PCRwas performed as previously described (22).
Primer sequences are listed in Supplementary Table 1.
Immunoblot. Protein levels were detected using antibodies against pla2g2a
(Abcam), glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Sigma-Aldrich),
phospho-hormone-sensitive lipase (HSL) (Ser563), and HSL (Cell Signaling).
Bands were analyzed using ImageJ 1.40e software.
Cell culture. Human mastocytoma cell line (HMC-1) cells were cultured in
Iscove’s modified Dulbecco’s medium (IMDM). Jurkat E6.1 and human acute
monocytic leukemia cell line (THP-1) cells were cultured in RPMI. Human
peripheral blood mononuclear cells (PBMCs) and monocyte-derived macro-
phages (HMDMs) were cultured in IMDM. 3T3-L1 fibroblasts were differenti-
ated 2 days after confluence, and fully differentiated adipocytes were used for
experiments such as the cAMP-Glo assay (Promega).
PBMC and HMDM isolation. PBMCs and HMDMs were harvested from buffy
coat of anonymous human donors (Australian Red Cross Blood Service,
Brisbane). For HMDMs, cluster of differentiation (CD) 14+ monocytes were
isolated using magnetic sorting (Miltenyi Biotech), then differentiated using
macrophage-colony stimulating factor.
Enzyme-linked immunosorbent assay. Cells were pretreated with KH064
(10 mmol/L) for 15 min before experiments. Culture supernatant, serum, and
adipose tissue homogenate PGE2 and insulin concentrations were determined
using a PGE2 metabolite and a rat insulin kit, respectively.
Physiologic parameters. Oral glucose tolerance and clearance tests were
previously described. For glucose tolerance, a glucose load of 2 g/kg body
weight was used for glucose tolerance and an insulin load of 0.3 IU/kg was used
for insulin tolerance (21). Plasma lipids and enzyme concentrations were
measured by The University of Queensland Veterinary Pathology Service (21).
Systolic blood pressure was measured as described (23).
Echocardiographic studies, heart preparation, and histopathologic analysis.
Echocardiographic examination was performed after 16 weeks as described (21).
Evaluation of the left ventricular function of all rats in all treatment groups after
16 weeks was performed as described (21). Histopathologic analysis of the heart,
liver, and adipose was performed as described (21,23).
Total lipid content. Extraction of tissue and fecal lipids was undertaken by
manual solvent extraction as described (24).
Drug. The inhibitor KH064 of pla2g2a was synthesized, purified, and enzy-
matically characterized as described (compound 2b in [25]). It binds in the
active site of human pla2g2a (25) and is a potent inhibitor of enzymatic activity
(half-maximal inhibitory concentration [IC50] 0.029 mmol/L). This enzyme is
similar to human macrophage pla2g5 enzyme against which KH064 is 100
times less potent (IC50 2 mmol/L (26)). The rat homolog of human pla2g2a was
not commercially available. KH064 does not bind or inhibit cPLA2 or iPLA2
enzymes (unpublished data from D.P.F.). We have reported pharmacokinetics
for KH064 given to rats intravenously (27) and orally (28). At a 5 mg/kg p.o. dose
(as used herein), KH064 was detectable in plasma within 15 min at relatively
constant concentrations for 6 h with Cmax ;0.2 mg/mL, Tmax ;2 h, and ;4%
oral bioavailability (area under the curve orally/area under the curve in-
travenously). KH064 was ;0.05 mg/mL in plasma 18–24 h after oral dosing,
suggesting partitioning to tissues (28). KH064 has been administered to mice
at 300 mg/kg/p.o. in a single dose with no substantive toxic effects, and it has
no significant off-target effects in a screen against 25 enzymes and 30 human
G protein-coupled receptors (unpublished data from D.P.F.). KH064 is pro-
gressing to clinical development.
Statistical analysis. Data were plotted and analyzed using GraphPad Prism
v5.00 software (GraphPad Software, San Diego, CA). Statistical differences in
pairwise comparisons between treatments were assessed using the Student
t test, and changes in body weight were assessed by two-way ANOVA
(*P ,0.05, **P , 0.01, and ***P , 0.001). All values of independent parameters
are mean 6 SEM (n $ 3 independent experiments) unless stated otherwise.
RESULTS
Pla2g2a but not pla2g16 is upregulated in rat adipose
by HCHF feeding. Our first objective was to investigate
which phospholipase could be a potential therapeutic
target to prevent adiposity and metabolic dysfunction. In-
creased PLA2 expression in adipose tissue might dampen
lipolysis through PGE2-EP3-Gai-cAMP signaling, promoting
adipocyte and metabolic dysfunction together with car-
diovascular symptoms of metabolic syndrome (14). Rats
were fed a HCHF diet to induce adiposity and symptoms of
metabolic syndrome (21). Relative to rats fed a CS diet,
those receiving the HCHF diet for 16 weeks became obese,
gaining 54 6 4% weight from weeks 0 to 16 and 112 6 17%
total visceral fat compared with CS rats (21). We measured
mRNA expression in adipose tissue of PLA2 isozymes
recognized for their roles in inflammation (pla2g2a,
pla2g4a, pla2g5, pla2g7, and pla2g10) or lipid metabolism
(pla2g6 and pla2g16). Expression of pla2g2a, pla2g6,
pla2g4a, pla2g7, and pla2g10 genes was extremely low in
CS-fed rats but significantly elevated in HCHF-fed obese
rats. Among these, PLA2 enzymes were somewhat upre-
gulated in response to HCHF feeding; pla2g2a mRNA ex-
pression was strikingly elevated by ;20-fold (Fig. 1A).
Correspondingly, pla2g2a protein expression was also
substantially increased in adipose tissue from HCHF-fed
obese rats compared with CS-fed normal rats (Fig. 1B).
Plasma and whole adipose tissue PGE2 concentrations
were elevated by HCHF compared with CS feeding, cor-
relating with increased adiposity (Fig. 1C and D). We
compared pla2g16 mRNA expression in rat adipose tissue
because this enzyme reportedly regulates adipocyte func-
tion and lipid metabolism in mice and is overexpressed in
ob/ob mice adipose tissue. Pla2g16 was expressed in rat
adipose tissue, but expression was unchanged by HCHF
feeding (Fig. 1A and Supplementary Fig. 1A). In an isolated
experiment, pla2g16 gene expression was unchanged in
adipose tissue from lean mice and diet-induced obese mice
after 16 weeks (Supplementary Fig.1B).
KH064 attenuates adiposity in diet-induced obese
rats. KH064 is an orally active, potent, and isoform-
selective inhibitor of pla2g2a. We have reported a crystal
structure for this inhibitor in complex with pla2g2a (25)
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and anti-inflammatory activity for this compound (25–28).
The increased adiposity exhibited by rats fed a HCHF diet
for 16 weeks (Fig. 2) was attenuated by oral administration
of KH064 (5 mg/kg/day) between weeks 8 and 16, with
marked prevention of body weight gain (weeks 8–16 HCHF,
19 6 1%; +KH064, 9 6 1%; Fig. 2A and B) and total visceral
fat deposition (+KH064, Fig. 2C–E). Treatment with KH064
also attenuated retroperitoneal and omental fat rather than
epididymal fat deposition (Fig. 2E). Further, administra-
tion of KH064 daily between weeks 8 and 16 to CS-fed
rats, which expressed only low pla2g2a, did not exhibit
any overt symptoms of toxic side effects or cause changes
in body weight (data not shown). Besides improvements
in adiposity, KH064 treatment from weeks 8 to 16 attenu-
ated increases in plasma and whole adipose tissue PGE2
concentrations in HCHF rats (Fig. 3A and B). Adipose
tissue immunohistochemistry demonstrated that treatment
with KH064 also prevented the significant increase in
crown formation and macrophage infiltration measured by
ED1 staining (Supplementary Fig. 1C and D). Further, in-
vestigating the polarization of infiltrated and resident macro-
phages in adipose tissue using inflammatory/surface marker
gene expression to profile M1- versus M2-macrophages (29)
suggested that HCHF-fed rats had increased expression of
M1-specific genes in adipose tissue in contrast to CS-fed
rats (Supplementary Fig. 1E and F). Treatment with KH064
normalized this trend to a more M2-like population in the
adipose tissue comparable to CS-fed rats (Supplementary
Fig. 1E and F).
Pla2g2a overexpression and inhibitor action in immune
cells, not adipocytes. Separation of whole adipose tis-
sue into adipocyte and SVC fractions confirmed that
pla2g2a was mainly expressed in the SVC fraction rather
than adipocytes in adipose tissue. Furthermore, HCHF
feeding induced overexpression of pla2g2a, but only
in the SVC (Fig. 3C). In contrast, pla2g16 was predom-
inantly expressed in the adipocyte fraction from whole
adipose tissue (Supplementary Fig. 1B), and its expres-
sion levels were not affected by HCHF feeding (as shown
in Fig. 1A).
The pla2g2a enzyme is an important generator of in-
flammatory lipid mediators during immune cell activation,
including PGE2 produced by cyclooxygenase (15,19,20).
We focused on PGE2 because it is implicated as a major
paracrine antilipolytic factor in adipocytes (14,30). We
found that PGE2 inhibited cAMP production in 3T3-L1
adipocytes and established the involvement of EP3 re-
ceptor and pertussis toxin–sensitive Gai-proteins in this
process (Supplementary Fig. 2A and B). In line with our in
vitro results, exogenous addition of PGE2 to rat whole
FIG. 1. RT-PCR gene expression of different PLA2 enzymes and protein expression of pla2g2a in rat adipose tissue. A: Quantitative comparison of
mRNA expression level of PLA2 enzymes in adipose tissue from rats fed CS vs. HCHF diets for 16 weeks. Values of PLA2 mRNA levels were
normalized relative to the housekeeping gene 18S rRNA. B: Immunoblot of pla2g2a protein levels in adipose tissue with glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) used as a loading control. Each lane represents adipose tissue homogenate from a single rat. Optical density of protein
bands was determined using ImageJ software. Serum (C) and adipose (D) homogenate concentrations of PGE2 from CS vs. HCHF fed rats. Error bars
represent means 6 SEM (n = 3–5 animals). *P < 0.05, **P < 0.01, ***P < 0.001.
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adipose tissue explants decreased glycerol release con-
sistent with reduced lipolysis (Supplementary Fig. 2C).
To establish that pla2g2a was primarily expressed in the SVC
and that this was where KH064 was acting, we pretreated
SVC with KH064 before lipopolysaccharide (LPS) stimu-
lation. LPS stimulated PGE2 production in the SVC, and
this was inhibited by KH064 (Fig. 3D). Further, at a rela-
tively high concentration (1 mmol/L), KH064 did not inhibit
any PLA2 enzymatic activity in adipose tissue from CS-fed
rats, confirming that KH064 did not inhibit pla2g16 or other
PLA2 enzymes in adipose tissue (Supplementary Fig. 3).
These results clearly trace the pharmacologic responses of
KH064 on pla2g2a to the immune cell–rich SVC in whole
adipose tissue and not the adipocyte fraction.
Regulation of lipolysis via pla2g2a and PGE2 in
immune cells. Many types of resident and infiltrated im-
mune cells, including macrophages, monocytes, T cells
and mast cells, contribute to adipocyte dysfunction (5–7).
However, their relative roles and importance in lipid ho-
meostasis and adipocyte function in obesity are not yet
clear. In this study, we investigated whether some or all of
these cells regulate lipolysis via pla2g2a/PGE2 in adipose.
Because we were not able to isolate infiltrated rat adipose
tissue immune cells in sufficient quantity or purity for in
vitro studies, we chose five primary or cultured human cell
types that are closely associated with adiposity and met-
abolic dysfunction. The five immune cell types—HMDM,
PBMC, HMC-1, Jurkat, and THP-1—all showed increased
PGE2 production after stimulation with palmitic acid, the
most common and abundant nutritional fatty acid in
Western-style diets that plays a major role in inducing
adipocyte and metabolic dysfunction in obese subjects
(31). Treatment of each cell type with KH064 markedly
reduced (two- to fivefold) this increased PGE2 production
(Fig. 4). To support the notion that KH064 was inhibiting
palmitic acid-induced PGE2 production via the pla2g2a
enzyme in these cell types, LPS was separately used to
elicit PGE2 production in these five immune cell types
(Supplementary Fig. 4). HMDM, PBMC, and HMC-1 showed
increased PGE2 production after LPS stimulation, and
KH064 treatment markedly reduced the increased PGE2
production in these cells (Supplementary Fig. 4). However,
there was no significant PGE2 increase in Jurkat and THP-1
cells after stimulation with LPS. This suggests that, in ad-
dition to macrophages (8), other immune cell types, such as
monocytes, T cells, and mast cells, may also secrete anti-
lipolytic factors, such as PGE2, to reduce lipolysis and free
fatty acid concentrations, thereby promoting adiposity.
Pla2g2a and PGE2 inhibition restores lipolysis in vivo.
One approach to improve adipocyte function is to de-
crease fat stores in adipose tissue by stimulating lipolysis
and oxidation of released fatty acids (13). Because the
pla2g2a inhibitor KH064 normalized lipolysis and attenu-
ated adiposity, we investigated whether inhibiting PGE2 in
vivo stimulated enhanced release of fat from adipose to-
ward better fat utilization and oxidation in the liver and
skeletal muscle. Phosphorylation of HSL through cAMP-
mediated activation of protein kinase A is a key mediator
of increased lipolysis in adipose tissue (14). HCHF-fed rats
decreased phosphorylation of HSL (Ser563) in adipose
compared with CS-fed rats (Fig. 5A). Treatment with KH064
from weeks 8 to 16 normalized or increased lipolysis
in adipose of HCHF rats by preventing this decrease in HSL
phosphorylation, without altering total HSL protein expres-
sion (Fig. 5A). In addition, genes involved in lipid metab-
olism and the lipolytic cascade, such as peroxisome
FIG. 2. KH064 modulates diet-induced adiposity in vivo in rats. A: Daily body weights for HCHF-fed rats (n = 10) alone or with daily oral treatment
with KH064 (5 mg/kg; HCHF+KH064, n = 10) from weeks 8 to 16. B: Cumulative percentage weight gain for HCHF-fed rats (n = 10) alone or with
daily oral treatment with KH064 (5 mg/kg; HCHF+KH064, n = 10) from weeks 8 to 16. C: Representative photographs show comparison of visceral
fat in rats at 16 weeks after different treatments. D: Total adiposity and depot specific adiposity for rats from different treatment groups (n = 6).
Error bars represent means6 SEM. *P< 0.05, **P< 0.01, ***P< 0.001. (A high-quality color representation of this figure is available in the online
issue.)
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proliferator-activator receptor-g (Pparg), Ppargc1a, uncou-
pling protein 2 (Ucp2), adiponectin (Adipoq), adipose tri-
glyceride lipase/desnutrin (Atgl), and Hsl in adipose tissue
were all normalized or increased with KH064 treatment
compared with CS-fed and HCHF-fed rats, respectively (Fig.
5B). Plasma nonesterified fatty acids were increased with
KH064 treatment compared with untreated HCHF animals at
week 16, consistent with increased lipolysis from adipose
tissue stores (Fig. 5C).
During lipolysis, either through acute weight loss or
metabolic disease, macrophages have been proposed as
transporters of fatty acids from adipose and peripheral
tissues to liver for metabolism and energy production,
similar to involvement of macrophages in the reverse
cholesterol transport pathway during atherosclerosis (8,9).
HCHF rats showed increased total lipids and steatosis in
the liver at 16 weeks compared with CS-fed rats (Fig. 5D
and Supplementary Fig. 5). Activities of the plasma liver
enzymes, aspartate aminotransferase, and alanine amino-
transferase were higher in HCHF-fed compared with CS-
fed rats, suggesting mild liver dysfunction (Fig. 5E).
Treatment with KH064 from weeks 8 to 16 attenuated this
increase in liver enzymes (Fig. 5E). Further, the increased
lipid content in liver was not attenuated with KH064
treatment from weeks 8 to 16 (Fig. 5D). Histology analysis
showed that livers from KH064-treated rats had accumu-
lated fat droplets (Supplementary Fig. 5 and Fig. 5E).
Plasma concentrations of alkaline phosphatase increased
with KH064 treatment (Fig. 5E). Extractable fecal lipid
content increased with KH064 treatment, suggesting de-
creased absorption of fat from the intestines or increased
excretion of fat (Fig. 5F). Furthermore, genes involved in
lipid metabolism and energy expenditure in the liver, such
as Ppara, sterol regulatory element binding transcription
factor 1 (Srebf1), Ucp2, Pparg, and hepatic lipase (Lipc),
were suppressed in HCHF rats but increased or normal-
ized in HCHF rats treated with KH064 (Fig. 5G). In skeletal
muscle, carnitine palmitoyltransferase 1 (Cpt1) and Ucp2
genes involved in energy expenditure were suppressed in
HCHF rats but increased or normalized in HCHF rats
treated with KH064 (Fig. 5H). Other genes involved in fatty
acid oxidation and mitochondrial biogenesis, including
Pparg, Ppargc1a, and pyruvate dehydrogenase kinase 4
(Pdk4) in adipose, liver, and skeletal muscle (32,33), were
upregulated in KH064-treated compared with untreated
HCHF-fed rats (Fig. 5B, G, and H). However, further in-
vestigation is needed on the exact mechanisms by which
KH064 alters the expression of lipid-handling genes in liver
and skeletal muscle and its direct responses on these
metabolically relevant tissues.
Pla2g2a inhibitor KH064 promotes lipolysis and
protects against diet-induced metabolic syndrome.
Attenuation of adipocyte dysfunction or adiposity im-
proves metabolic and cardiovascular symptoms of meta-
bolic syndrome in animals and clinical studies (4,34–37). In
this study, alterations in metabolic parameters in HCHF-
fed compared with CS-fed rats included decreased ex-
pression of genes involved in glucose metabolism in the
pancreas (Fig. 6A), increased plasma insulin concen-
trations (Fig. 6B), impaired glucose and insulin tolerance
(Fig. 6C–E), increased systolic blood pressure (Supple-
mentary Table 2 and Supplementary Fig. 6), and abnor-
malities in cardiac structure and function (Fig. 6F–H).
Treatment with KH064 attenuated changes in glucose me-
tabolism genes in the pancreas, such as glucose transporter
2 (glut2), hexokinase, and mitochondria glycerophosphate
dehydrogenase (mGPDH) (38,39), while normalizing glu-
cose and insulin tolerance (Fig. 6C–E). Furthermore, most
FIG. 3. KH064 treatment modulates PGE2 concentrations in Wistar rats and SVCs. PGE2 concentrations in serum (A) and whole adipose tissue (B)
from rats fed a high carbohydrate high fat (HCHF) diet alone or with drug (KH064 5 mg/kg/day). C: Pla2g2a gene expression in whole adipose
tissue, adipocyte, and SVC fractions. D: Ex vivo treatment with KH064 inhibits LPS-induced PGE2 production in SVCs. Error bars represent
mean 6 SEM of least three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
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of the changes in cardiovascular structure and function in
HCHF-fed rats were attenuated by KH064 (Fig. 6A–H,
Supplementary Table 2, and Supplementary Fig. 6), in-
cluding excessive collagen deposition in the left ventricle
of the heart in HCHF rats.
DISCUSSION
This study reports important new evidence for involve-
ment of secretory phospholipase A2 enzyme, pla2g2a, in
diet-induced adiposity and metabolic and cardiovascular
dysfunction. Phospholipases are important in pathogenesis
of chronic inflammatory diseases and thought to be im-
portant in lipid metabolism. Here we show that the specific
isozyme pla2g2a is an important mediator in the cross talk
between immune and metabolic systems in adipose tissue,
relevant to lipid and energy homeostasis, metabolic, and
cardiovascular function. In HCHF-fed rats, pla2g2a was
upregulated in the SVC but not in the adipocyte fraction of
adipose tissue. The selective pla2g2a inhibitor (KH064) (25),
administered orally to HCHF-fed rats, was found herein
to inhibit the development of obesity, adiposity, insulin re-
sistance, and glucose intolerance. The pla2g2a inhibitor also
attenuated changes in other features of metabolic and car-
diovascular dysfunction induced by nutritional overload.
These in vivo effects of KH064 were linked to preventing
PGE2 release in adipose tissue from immune cells and not
adipocytes. Immune cells infiltrate adipose tissue during
obesity and metabolize fatty acids. Our hypothesis is that
these immune cells overexpress pla2g2a, generating metab-
olites of phospholipids, such as PGE2, to act on secondary
target cells (adipocytes) and inhibit lipolysis via a PGE2–
EP3–cAMP pathway. An inhibitor of pla2g2a has been
shown here to inhibit in vitro palmitate- or LPS-stimulated
release of PGE2 from macrophages, T cells, monocytes,
and mast cells, known to reside in adipose tissue of obese
humans (5,6,40). The differential responses of immune
cells to LPS- and palmitate-induced secretion of PGE2 may
involve other, as yet unknown, signaling mechanisms.
Palmitate-induced production of PGE2 may involve fatty
acid receptors, such as FFA1 (GPR40), FFA2 (GPR43),
FFA3 (GPR41), or GPR120 (41). Nonetheless, in vivo KH064
decreased plasma and adipose PGE2 concentrations, nor-
malized and stimulated lipolysis in adipose tissue, and
protected against adiposity in diet-induced obese rats. This
suggests a novel role for immune cells in regulating lipol-
ysis through EP3-Gai-cAMP signaling during diet-induced
obesity. PGE2 regulates adipocyte dysfunction and con-
tributes to antilipolytic pathways via EP3 receptors,
thereby decreasing cAMP concentrations (14). This is the
first study to show that modulating PGE2 secretion,
through inhibition of pla2g2a from key immune cells resi-
dent in and infiltrated to adipose, reverses diet-induced
adiposity and metabolic syndrome. However, we cannot
rule out improvements in metabolic parameters arising
from synergistic responses from KH064 acting on other
metabolically relevant tissues along with adipose, from
decreased intestinal fat absorption and altered lipid me-
tabolism, or through unknown off-target effects on nuclear
receptors such as constitutive active/androstane receptor
(CAR) or pregnane X receptor (PXR).
Some other PLA2 isozymes (pla2g16, pla2g6b, pla2g4a)
may be important in metabolism because their genetic
knockout prevented development of obesity (14,42–44).
However, both pla2g162/2 and pla2g6b2/2 phenotypes ex-
hibited severe defects in insulin secretion. In pla2g162/2mice,
FIG. 4. In vitro KH064 inhibits palmitic acid–induced PGE2 production in human immune cells. The production of PGE2 in culture supernatants was
analyzed by ELISA. HMDM, PBMC, Jurkat, HMC-1, and THP-1 secrete PGE2 elicited by palmitic acid (PA) and pretreatment of KH064 inhibits this
palmitic acid–induced PGE2 production. Error bars represent mean 6 SEM of least three independent experiments. *P < 0.05, **P < 0.01, ***P <
0.001.
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FIG. 5. In vivo responses of KH064 (5 mg/kg/day p.o., weeks 8–16) on the regulation of metabolic parameters that were elevated in rats fed HCHF
vs. CS diets for 16 weeks. A: Immunoblot of phospho-HSL (Ser563) in adipose tissue with total HSL as the loading control. Optical density of
protein bands was determined using ImageJ software. B: RT-PCR gene expression of genes in adipose tissue of rats fed CS and HCHF diets with
and without KH064 treatment. C: Plasma concentrations for lipids nonesterified fatty acids (NEFA), triglycerides, and total cholesterol in rats of
different groups (n = 5–10). D: Liver total lipid content in rats of different groups (n = 5). E: Plasma liver enzymes in rats of different groups (n =
5–10). F: Total soluble fecal fat in rats of different groups (n = 5). RT-PCR gene expression of different metabolic genes in liver (G) and skeletal
muscle (H). Values of mRNA levels were normalized relative to 18S rRNA. Error bars represent means 6 SEM (n = 3–5 animals). *P < 0.05, **P <
0.01, ***P < 0.001.
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insulin resistance was observed in normal and high-fat diets
(14), whereas pla2g6b2/2 mice were refractory to glucose-
stimulated insulin release (43). Similarly, contradictory evi-
dence on deposition of lipids in the liver was reported;
pla2g162/2 mice showing increased fat deposition in the
liver, whereas pla2g4a2/2 and pla2g6b2/2 had decreased
fat deposition in liver compared with wild types after high
fat feeding (43–45). There is growing evidence suggesting
that immune cells transport lipids from adipose to liver for
metabolism, but those studies did not investigate whether
deposition of lipids was transient or on-going or caused
liver damage. Moreover, pla2g16 was upregulated in ge-
netically modified mice (ob/ob and db/db) and in acute-fed
fasted mice (14). In our much longer-duration study,
pla2g16 gene expression was unchanged in adipose from
rats and mice (Supplementary Fig.1A) after 16 weeks of
HCHF feeding. Our findings differ from those reported for
pla2g16 in fasted acute-fed mice (14). It is conceivable that
pla2g16 might act early in a proinflammatory pathway re-
quired for immune cell infiltration. In the absence of
pla2g16, any increase in adipose tissue inflammation and
immune cell infiltration might have been blocked to pre-
vent an increase in adipose tissue PLA2 activity. However,
in our much longer chronic obesity experiments, it is clear
that pla2g2a is unique among sPLA2 isoforms examined in
being dramatically overexpressed in HCHF-fed rats com-
pared with CS-fed rats, and importantly, the pla2g2a-selective
inhibitor attenuated adiposity and most symptoms of meta-
bolic syndrome in these rats.
Activating inflammatory lipid mediators associated with
adipokines and cytokines to alter adipocyte and immune
cell function has now become the prevailing hypothesis
to explain mechanisms of metabolic and adipocyte dys-
function (4,46). Nutrient- and pathogen-sensing systems in
humans may have evolved together, possibly for more ef-
ficient management of energy homeostasis, metabolic
function, and immunity by coordinating energy storage,
transport, and metabolism (1,3). We speculate that re-
cruiting immune cells into adipose during obesity, and
associated metabolic dysfunction, is not only an inflam-
matory response to stress but also a mechanism to regu-
late energy metabolism. Weight loss by calorie restriction
is associated with macrophage recruitment to white adi-
pose tissue and regulation of lipid trafficking and lipolysis
(8,9). Our hypothesis is supported by recent studies in
which there was increased local release of fatty acids
during fasting, inducing recruitment of immune cells and
secretion of antilipolytic factors such as PGE2 to reduce
free fatty acid concentrations (8,9). Our results indicate
that resident and infiltrating immune cells in adipose have
FIG. 6. In vivo and ex vivo responses to KH064 (5 mg/kg/day p.o. for weeks 8–16) of the regulation of metabolic and cardiovascular parameters that
were elevated in rats fed HCHF vs. CS diets for 16 weeks. A: RT-PCR analysis of glucose metabolism genes in rat pancreas of different groups. B:
Plasma concentrations of insulin in rats of different groups (n = 5). C: Fasting blood glucose concentrations in rats of different groups (n = 6 for all
groups).D: Oral glucose tolerance tests (OGTT) in rats of different groups (n = 6 for all groups). E: Insulin tolerance test (ITT) in rats of different
groups (n = 6 for all groups). F: Representative images (original magnification 340) of interstitial collagen deposition in the left ventricle.
G: Quantitative measurement of the area of collagen deposition in the interstitial region of the left ventricle (n = 4 for all groups). H: Diastolic
stiffness constant of rats in different groups. Error bars represent mean 6 SEM (n = 3–5 animals). *P < 0.05, **P < 0.01, ***P < 0.001. (A high-
quality color representation of this figure is available in the online issue.)
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important signaling roles in regulating energy metabolism,
such as lipolysis and oxidation of released fatty acids, and
these signaling networks may be overloaded and dysfunc-
tional in obesity. Pharmacologic modulation of immune
cells can improve diet-induced adiposity and symptoms of
metabolic syndrome. Contrary to current opinion, increasing
or normalizing lipolysis as a pharmaceutic strategy or el-
evating plasma free fatty acids in obese subjects may not
necessarily translate into metabolic dysfunction or insulin
resistance (47). More dynamic and refined studies are re-
quired to clarify relationships and roles of specific fatty
acids in obesity and metabolic dysfunction, with greater
emphasis on consequences of impaired or dysfunctional
adipocyte fat storage, release, and function on adipokines/
cytokines that affect metabolism (47).
In summary, pla2g2a has been shown to be by far the
most upregulated Pla2 isozyme in adipose tissue of diet-
induced obese rats. This protein is localized to immune
cells in adipose tissue rather than to adipocytes. The study
raises the possibility that systemic pla2g2a inhibition may
decrease fat stores by preventing PGE2 biosynthesis from
immune cells in adipose tissue to stimulate lipolysis and
fatty acid oxidation. Importantly, KH064 is a potent and
specific inhibitor of human pla2g2a and prevents diet-induced
adiposity, insulin resistance, and metabolic and cardiac
dysfunction in rats. These results indicate that modulation
of adipose tissue homeostasis, by blocking an endocrine
and paracrine stimulus from immune cells rather than
adipocytes, may be a novel approach to treat diet-induced
metabolic syndrome in humans.
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